Drugs / GC3114
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03357263 | Nov → Dec 2017 | influenza | Green Cross Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03657719 | Oct → Dec 2018 | influenza | Green Cross Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC3114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03657719 ↗ |
| Known as | GC3114A | “Healthy adults will be once administered GC3114A(High-dose Quadrivalent influenza vaccine) or GCFLU Quadrivalent Pre-filled syringe inj..” NCT03357263 ↗ |
| Modality | Vaccine | “high-dose, quadrivalent inactivated influenza vaccine (HD-QIV)” PMID 31377075 ↗ Jul 2019 |
| Route | Intramuscular | “Pre-filled syringe inj., 0.5ml, Once, IM” NCT03357263 ↗ |